President Donald Trump announced on Thursday new agreements with drugmakers Novo Nordisk and Eli Lilly that will sharply cut prices on popular weight-loss drugs, marking one of the most significant pharmaceutical pricing deals in recent years.
Under the plan, Novo Nordisk will reduce the price of the lowest dose of Wegovy to $149 for a month’s supply, extending the discount across all of its direct-to-patient programs. The company confirmed it will also lower prices for Wegovy and Ozempic under Medicare Part D, Medicaid, and self-pay programs. Novo Nordisk said additional pricing updates for both drugs will be announced in the coming weeks.
Calling the move “a triumph for American patients,” Trump said the deal “will save lives and improve the health of millions and millions of Americans.”
Eli Lilly announced similar changes, cutting the starting price of its obesity drug Zepbound to $299 per month for the lowest dose and $449 for higher doses — about $50 less than its current direct-purchase price. Its forthcoming oral obesity treatment, Orforglipron, will also start at $149 for the lowest dose once approved. Medicare patients will pay no more than $50 per month for either Zepbound or Orforglipron. Lilly also plans to slash prices by 50–60% for other medications, including Mounjaro, Trulicity, and Emgality, through its LillyDirect platform.
GLP-1 drugs such as Wegovy, Ozempic, and Zepbound have revolutionized weight-loss treatment by mimicking the body’s natural appetite-regulating hormones. However, their high prices and limited insurance coverage have put them out of reach for many patients, while overwhelming demand has strained supply chains.
The White House said the deals align with Trump’s “Most Favored Nation” executive order aimed at lowering U.S. drug prices to levels comparable with those in other countries.
Both Novo Nordisk and Eli Lilly have launched direct-to-consumer programs designed to expand access. Novo Nordisk’s NovoCarePharmacy, launched earlier this year, and Lilly’s LillyDirect, introduced in early 2024, allow patients to bypass insurance hurdles and order medications directly.
The companies say the new pricing structures will make life-changing weight-loss drugs accessible to millions more Americans — a major milestone in the ongoing fight against obesity.